Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study

Blood Vessels Thrombosis & Hemostasis 2026 Open access

Read full text
Authors: Shruti Chaturvedi, Srikanth Nagalla, Scott Kolodny, Abiola O. Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Loren Ormenaj, Sinia Sareen, Jorge Nicolas Ruiz Lopez, Michael Vredenburg
+1 more Moshe Yair Levy
DOI: 10.1016/j.bvth.2026.100142
Cited by: 0
References: 14

Abstract

ABSTRACT (230/250 WORDS) The REAL-AVA 2.0 study was a retrospective multi-site chart review evaluating avatrombopag (AVA) effectiveness among patients with primary immune thrombocytopenia (ITP) who underwent routine care in academic- and community-based practices in the United States and initiated AVA between July 1, 2019 and June 30, 2024. Treatment response was defined as achieving platelet counts (PC)≥30k/μL, PC≥50k/μL, or PC≥100k/μL. The discontinuation of steroids and/or immunosuppressants after AVA initiation was evaluated. Analyses were performed in the overall population and among two stratified subgroups: ITP disease duration (acute:

Fields of Study & Subjects

Platelet Disorders and Treatments Heparin-Induced Thrombocytopenia and Thrombosis Antiplatelet Therapy and Cardiovascular Diseases

Publication details

Journal / source
Blood Vessels Thrombosis & Hemostasis
Volume
3
Issue
2
Pages
100142–100142
Publication date
3 February 2026
Language
EN